Expedition Therapeutics Raises $115 Million as COPD Phase 2 Starts
Expedition Therapeutics closed an oversubscribed $115 million Series B led by General Atlantic, with RA Capital, Vivo Capital and all existing investors participating. The company simultaneously disclosed first-patient dosing in its global Phase 2…
